Little Green Pharma (ASX:LGP) EBITDA: A$2.72 Mil (TTM As of Mar. 2026)


What is Little Green Pharma EBITDA?

Little Green Pharma ASX:LGP EBITDA is A$2.72 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Little Green Pharma's EBITDA for the six months ended in Mar. 2026 was A$1.48 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$2.72 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 7 years, the highest 3-Year average EBITDA Growth Rate of Little Green Pharma was 20.20% per year. The lowest was 20.20% per year. And the median was 20.20% per year.

Little Green Pharma's EBITDA per Share for the six months ended in Mar. 2026 was A$0.01. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 7 years, the highest 3-Year average EBITDA per Share Growth Rate of Little Green Pharma was 39.90% per year. The lowest was 39.90% per year. And the median was 39.90% per year.

Little Green Pharma  (ASX:LGP) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Little Green Pharma EBITDA Related Terms


Little Green Pharma EBITDA Historical Data

* Premium members only.

The historical data trend for Little Green Pharma's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Little Green Pharma EBITDA Chart

Little Green Pharma Annual Data
Trend Jun19 Jun20 Jun21 Mar23 Mar24 Mar25 Mar26
EBITDA
Get a 7-Day Free Trial 25.38 -4.57 -4.47 -0.74 2.72

Little Green Pharma Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.77 -1.44 0.70 1.24 1.48

ASX:LGP vs ZTS: EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Little Green Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Little Green Pharma EV-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Little Green Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Little Green Pharma's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Little Green Pharma's EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

Little Green Pharma's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Mar. 2026, Little Green Pharma's EBITDA was A$2.72 Mil.

Little Green Pharma's EBITDA for the quarter that ended in Mar. 2026 is calculated as

Little Green Pharma's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2026, Little Green Pharma's EBITDA was A$1.48 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of A$2.72 Mil mean?
Little Green Pharma (ASX:LGP) has a EBITDA of A$2.72 Mil as of Mar. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Little Green Pharma.
Is Little Green Pharma's EBITDA too high?
Little Green Pharma's current EBITDA is A$2.72 Mil.
How does Little Green Pharma's EBITDA compare to ZTS?
Little Green Pharma's EBITDA of A$2.72 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Drug Manufacturers company?
A good EBITDA depends on the Drug Manufacturers industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Little Green Pharma. Little Green Pharma's current EBITDA is A$2.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Little Green Pharma stock overvalued right now?
Based on GuruFocus' analysis, Little Green Pharma (ASX:LGP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.17, compared to a current price of A$0.06 — trading 62.4% below its estimated fair value. The current EBITDA is A$2.72 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Little Green Pharma (ASX:LGP), the current EBITDA is A$2.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Little Green Pharma Business Description

Address 13A Bedbrook Place, Shenton Park, West Perth, Perth, WA, AUS, 6008
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets. The Group is organized into two operating segments: Australia and Europe (cultivation, production and distribution of cannabis products to Australian and European customers).